Contact
searchSearch
HMP Global
Login

Genitourinary Cancer Videos

Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Zibelman Headshot
Videos
Exploring the Potential of Nivolumab and Axitinib in Renal Cell Carcinoma
03/11/2025
Matthew Zibelman, MD
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares...
03/11/2025
Journal of Clinical Pathways
Doshi Headshot
Videos
Assessing Real-World Outcomes of First-Line Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma
02/18/2025
Sahil Doshi, MD
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi,...
02/18/2025
Journal of Clinical Pathways
Headshot
Videos
The Role of ctDNA Clearance in RCC: Retrospective Analysis and Clinical Implications
02/13/2025
Adanma Ayanambakkam, MD
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma...
02/13/2025
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Dr Rana McKay.
ENGAGING EXPERTS
Antitumor Activity of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
06/19/2023
Rana McKay, MD
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary...
06/19/2023
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use